InnovAge HoldingINNV +3.05%72 EBITDA Margin % is -9.51% as of Mar. 2026. GuruFocus rates INNV with a GF Score™ of 72/100 and a GF Value™ of $6.52 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 668 Healthcare Providers & Services companies, InnovAge Holding ranks worse than 72.01% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. InnovAge Holding's EBITDA for the
three
months ended in Mar. 2026 was $-24.0 Mil. InnovAge Holding's Revenue for the
three
months ended in Mar. 2026 was $251.9 Mil. Therefore, InnovAge Holding's EBITDA margin for the quarter that ended in Mar. 2026 was -9.51%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
InnovAge Holding EBITDA Margin % Related Terms
InnovAge Holding EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for InnovAge Holding's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INNV vs USPH, AMN, NUTX: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, InnovAge Holding's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnovAge Holding EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, InnovAge Holding's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where InnovAge Holding's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnovAge Holding (INNV) has a EBITDA Margin % of -9.51% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on InnovAge Holding and its competitors. According to the industry distribution chart, InnovAge Holding ranks #481 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 72%.
Is InnovAge Holding's EBITDA Margin % too high?
InnovAge Holding's current EBITDA Margin % is -9.51%. Based on the distribution chart, InnovAge Holding ranks #481 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, InnovAge Holding has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does InnovAge Holding's EBITDA Margin % compare to USPH and AMN?
According to the Healthcare Providers & Services industry distribution chart, InnovAge Holding ranks #481 out of 668 companies for EBITDA Margin %. This places InnovAge Holding in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on InnovAge Holding and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnovAge Holding's current EBITDA Margin % is -9.51%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnovAge Holding stock overvalued right now?
Based on GuruFocus' analysis, InnovAge Holding (INNV) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.52, compared to a current price of $9.97 — trading 52.8% above its estimated fair value. The current EBITDA Margin % is -9.51%. InnovAge Holding's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For InnovAge Holding (INNV), the current EBITDA Margin % is -9.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnovAge Holding (INNV) Overvalued in 2026?
Based on GuruFocus' analysis, InnovAge Holding stock appears to be overvalued.
The current stock price of $9.97 is trading 52.8% above its estimated GF Value™ of $6.52.
GuruFocus considers InnovAge Holding to be Significantly Overvalued.
Key valuation signals for INNV:
EBITDA Margin %: -9.51%
GF Value™: $6.52 vs. price of $9.97 (52.8% above fair value)
No single metric tells the full story. See the INNV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnovAge Holding Corp is a healthcare delivery platform comprising multiple participants focused on providing all-inclusive, capitated care to high-cost seniors, many of whom are dual-eligible. Its programs are designed to address two of the pressing challenges facing the U.S. healthcare industry: rising costs and poor outcomes. The purpose of the participant-centered care delivery approach is to improve the quality of care participants receive, while keeping them in their homes for as long as possible and reducing the overutilization of high-cost care settings, such as hospitals and nursing homes. The company manages its business as one reportable segment, PACE.
72GF Score
Get the complete analysis for INNV
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INNV has been successfully added to your 
